Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis:A case report
作者机构：Department of Pulmonary and Critical Care MedicineFirst Affiliated Hospital of Dalian Medical UniversityDalian 116011Liaoning ProvinceChina Department of PathologyFirst Affiliated Hospital of Dalian Medical UniversityDalian 116011Liaoning ProvinceChina
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2022年第10卷第5期
页 面：1716-1722页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：Supported by the Dalian Municipal Science and Technology Innovation Foundation No.2020JJ27SN072
主 题：Vedolizumab Adverse effects Ulcerative colitis Inflammatory bowel disease Interstitial lung disease Case report
摘 要：BACKGROUND Vedolizumab,a newer class of integrin antagonist biological agents,has been applied to treat patients with moderate-to-severe Crohn’s disease(CD)and ulcerative colitis(UC),especially for patients who are refractory to traditional therapies and tumor necrosis factor ***,some rare but lifethreatening adverse effects warrant *** describe the first fatal case of vedolizumab-associated severe diffuse interstitial lung disease in *** SUMMARY We present a case of new-onset diffuse parenchymal lung disease developing under treatment with vedolizumab in a patient with *** two doses of vedolizumab,he developed persistent fever and progressively worsening *** workups,including bronchoalveolar lavage,transbronchial lung biopsy and metagenomic next-generation sequencing,identified no infectious causes,and other potential causes(such as tumors and cardiogenic pulmonary edema)were also *** a result,a diagnosis of vedolizumabrelated interstitial lung disease was ***,although corticosteroids and empiric antibiotics were administered,the patient eventually died of respiratory *** Vedolizumab-related interstitial lung disease in patients with UC is rare but potentially *** and pulmonologists should be aware of vedolizumab-related adverse drug reactions.
维普期刊数据库